Technical Overview
On the daily chart, the stock rallied strongly from around $750 to above $1100 and is now consolidating inside an ascending channel.
Price is currently testing the lower boundary of the channel, which acts as a key support zone together with a major moving average.
If this support holds, the stock could continue moving upward within the channel. A breakdown could lead to a deeper correction.
Short-Term Outlook
If the price stabilizes above $1020–$1030, buyers may regain control.
Targets
• $1050
• $1080
• $1120 (channel resistance)
Stop Loss
• Below $995
If this level breaks, the next downside levels are $960 and $930.
Long-Term Outlook
The long-term trend remains bullish, and the current movement looks like a consolidation phase after a strong rally.
Targets
• $1180
• $1250
• $1350
Long-Term Stop Loss
• Below $930
Brief Fundamental View
Eli Lilly and Company remains one of the fastest-growing pharmaceutical companies, driven by strong demand for diabetes and weight-loss drugs such as Mounjaro and Zepbound.
Despite competition from Novo Nordisk, long-term growth expectations for the company remain strong.
On the daily chart, the stock rallied strongly from around $750 to above $1100 and is now consolidating inside an ascending channel.
Price is currently testing the lower boundary of the channel, which acts as a key support zone together with a major moving average.
If this support holds, the stock could continue moving upward within the channel. A breakdown could lead to a deeper correction.
Short-Term Outlook
If the price stabilizes above $1020–$1030, buyers may regain control.
Targets
• $1050
• $1080
• $1120 (channel resistance)
Stop Loss
• Below $995
If this level breaks, the next downside levels are $960 and $930.
Long-Term Outlook
The long-term trend remains bullish, and the current movement looks like a consolidation phase after a strong rally.
Targets
• $1180
• $1250
• $1350
Long-Term Stop Loss
• Below $930
Brief Fundamental View
Eli Lilly and Company remains one of the fastest-growing pharmaceutical companies, driven by strong demand for diabetes and weight-loss drugs such as Mounjaro and Zepbound.
Despite competition from Novo Nordisk, long-term growth expectations for the company remain strong.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.